top of page
Direction et Conseil d'administration
max.png

Massimiliano Paganelli, MD, PhD​

Co-fondateur et Chef de la direction par intérim

Max est hépatologue en transplantation pédiatrique, chef du Laboratoire d’ingénierie tissulaire hépatique et thérapie cellulaire au CHU Sainte-Justine et professeur agrégé de pédiatrie à l’Université de Montréal. Il a obtenu son diplôme de médecine à l’Université Sapienza de Rome et a suivi une formation en pédiatrie à Rome et en hépatologie pédiatrique et en transplantation à Naples et à Bruxelles. Max est également titulaire d’un doctorat en hépatologie et thérapie cellulaire de l’Université catholique de Louvain. Expert en thérapie cellulaire des maladies du foie, il est chercheur du Réseau de cellules souches qui est financé par les IRSC et le FRQS. Un initiative poussé par les besoins de ses jeunes patients, Max est à la recherche de meilleures façons de traiter les maladies du foie à l’aide de nouvelles thérapies fondées sur les cellules souches. Max dirige Morphocell en tant que président et chef de la direction depuis 2019.

claudia.png

Claudia Raggi, MD

Co-fondatrice et Directrice de la technologie

 

Claudia est une experte en développement humain et en différenciation des cellules souches. Formée en médecine à l’Université de Rome La Sapienza et à l’Université catholique de Louvain, Claudia est une scientifique en recherche translationnelle à temps plein depuis 2009.  Elle a inventé la technologie de plateforme iPSC de Morphocell, avec une expertise unique dans le développement préclinique de produits de thérapie cellulaire et la de fabrication de cellules. Claudia a mis en place et dirige une équipe passionnée d'ingénieurs et de scientifiques qui mènent les thérapies innovantes de Morphocell en clinique.

Margaret Bywater Ekegard, MD, MSc

Co-fondatrice et membre du 

 

A   senior   executive   with   extensive experience in building biotechnology and life science-related businesses, Maggie is accomplished in identifying and commercializing technologies, as well as successfully bringing new classes of products to market in global biotech industry. With extensive experience of start-ups, and managing growth in small businesses, as well as in global organizations, she is a business developer and deal maker with over thirty years of industry experience in integration of technologies to answer difficult biological questions. Maggie co-founded Morphocell and has been leading the Company as an active member of Board of Directors since the very beginning.

Cynthia Lavoie, PhD, MBA

Member of the BOD

 

Cynthia is currently President and Chief Investment Officer of CCRM Enterprises Ltd., responsible for the investment portfolio. Cynthia is also a Managing Director of AllosteRx Capital, an early-stage venture capital firm she co-founded in 2018. She earned her MBA with first class honors from Rotman School of Management at the University of Toronto and earned her PhD in Molecular Biology with Dean’s honors from McGill University. Before founding AllosteRx Capital, Cynthia was a General Partner with TVM Capital, a global fund with main offices in Munich and Montreal, and partner and co-head of the life sciences fund at VG Partners before that. Cynthia seats on many boards and is an independent member of Morphocell's BOD since 2022. 

Susan Burkman, MBA, CPA

Member of the BOD

Susan is an experienced financial consulting executive with 35 years of experience in the investment banking industry. She has successfully led equity, M&A, and valuation and fairness opinion transactions in excess of $6 billion for Canadian companies across numerous industries. She is president of Burkman Capital Corporation, an investment banking boutique located in Bromont, Québec. She holds both a Bachelor of Arts degree and Masters of Business Administration degree from the University of Pittsburgh and became a Certified Public Accountant in Pennsylvania. Among her many previous experiences, she was a partner at Griffiths McBurney and Partners and a Director at GMP Securities where she led the Investment Banking Group in Montreal. Susan has been working with Morphocell since its very beginnings, and is a member of its BOD since 2022.

bottom of page